Abstract: User equipment includes one or more antennas, a receiver coupled to the one or more antennas, and processing circuitry coupled to the receiver and configured to cause the user equipment to receive downlink signals at each communication cycle using a predetermined beam in a beam time slot. Based on processed downlink signals and other relevant information the user equipment may determine a desired beam for the next communication cycle. If the desired beam is the same as the predetermined beam, the user equipment may continue using the predetermined beam at the next communication cycle. If the desired beam is different from the predetermined beam, the user equipment may switch to the desired beam at the next communication cycle. In this way, the user equipment may continue tracking a desired beam to maintain reliable data communications with a communication node.

Abstract: Frequency spectrum of wireless transmission signals are allocated based on availability and regulatory requirements. To ensure transmission signals are within designated channel boundary, user equipment utilizes processing circuitry coupled to a transceiver to pre-compensate for estimated frequency shift at the time of transmissions. Certain guard bands are provided such that the actual transmission signals with the frequency pre-compensation are within the designated channel boundary. Additionally, or alternatively, the user equipment utilizes the processing circuitry to pre-compensate for estimated time shift based on a crystal drift using temperature measurement.

Abstract: User equipment includes one or more antennas, a receiver coupled to the one or more antennas, and processing circuitry coupled to the receiver and configured to cause the user equipment to receive downlink signals at each communication cycle using a predetermined beam in a beam time slot. Based on processed downlink signals and other relevant information the user equipment may determine a desired beam for the next communication cycle. If the desired beam is the same as the predetermined beam, the user equipment may continue using the predetermined beam at the next communication cycle. If the desired beam is different from the predetermined beam, the user equipment may switch to the desired beam at the next communication cycle. In this way, the user equipment may continue tracking a desired beam to maintain reliable data communications with a communication node.

Abstract: An electronic device includes a transceiver and processing circuitry communicatively coupled to the transceiver and configured to transmit uplink signals to a secondary communication node in response to determining that an uplink beam of a primary communication node is non-functional while continuing to receive downlink signals from the primary communication node using a downlink beam. Using multi-beam coverage by multiple communication nodes provide more reliable communications for the electronic device when a beam of a communication node is non-functional.

Abstract: User equipment includes a receiver, a first antenna and a second antenna coupled to the receiver, and processing circuitry communicatively coupled to the receiver and configured to cause the receiver to receive a first signal via the first antenna and a second signal via the second antenna, adjust the first signal based on a first time offset and a first frequency offset associated with the first signal to generate a first adjusted signal, adjust the second signal based on a second time offset and a second frequency offset associated with the second signal to generate a second adjusted signal, and decode downlink information based on the first adjusted signal and the second adjusted signal.

Abstract: The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.

Abstract: The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.

Abstract: The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.

Abstract: The invention relates to nicotinamide riboside or a derivative thereof for use in the treatment and/or prevention of liver or pancreatic cancer in a subject. Additionally, the invention relates to an in vitro method for designing a customized therapy for a subject diagnosed with a liver cancer or pancreatic cancer or suffering early signs of chronic liver damage or pancreatic intraepithelial lesions based on determining the level of DNA damage. Additionally the invention also relates to a method for diagnosing liver cancer and for predicting the risk of developing liver cancer in a subject suffering hepatitis. The invention also relates to a kit and their use in the methods of the invention.

Abstract: The invention provides methods and compositions (such as for example, culture media) for culturing Clostridium difficile and producing the C. difficile Toxins A and B.

Abstract: The invention provides methods and compositions (such as for example, culture media) for culturing Clostridium difficile and producing the C. difficile Toxins A and B.

Abstract: The invention provides methods and compositions (such as for example, culture media) for culturing Clostridium difficile and producing the C. difficile Toxins A and B.